单个淋巴结转移（Ns）在口腔鳞状细胞癌（OSCC）患者中有时会出现。不同Ns的生存结果值得讨论。回顾了2007年1月至2018年12月在台湾大学医院诊断为OSCC的患者。所有有Ns的患者分为两组：有和没有淋巴结外扩（ENE）。我们分析了311名有Ns的OSCC患者：其中77人（24.76％）有ENE，234人（75.24％）没有ENE。淋巴结（LN）>3厘米是与ENE相关的唯一重要因素（OR值为17.21，p＜0.001）。 N1 / N2A和N3B患者的5年无病生存率分别为60.5％和49.4％（p = 0.04），5年总生存率分别为63.1％和33.6％（p = 0.0001）。 针对LN>3厘米的Ns患者中的四分之四被升级为ENE+的N3B类别。术后放疗（PORT）可以为具有和不具有其他不良特征的Ns患者提供区域控制的显著益处（p = 0.03和p = 0.0004）。经过多因素Cox分析，ENE +是无病生存率（p = 0.08）和总生存率（p = 0.001）的轻微但显著的风险因素。相比之下，LN> 3厘米和N2A类别对于无病生存率和总生存率并不是显著的风险因素。对于具有Ns的OSCC患者而言，N3B类别和N1 / N2A类别之间的生存结局差异显著。ENE +升级后（>80％），N2A患者更少，并且这些患者与N1患者更具可比性。对于Ns患者，PORT可以显著改善区域控制。 ©2023年。外科肿瘤学协会。

The presence of single-node metastasis (Ns) sometimes could be encountered in patients with oral squamous cell carcinoma (OSCC). The survival outcome for different Ns should be worthy of discussion.Patients diagnosed with OSCC at the National Taiwan University Hospital between January 2007 and December 2018 were reviewed. All patients with Ns were classified into two groups: with and without extranodal extension (ENE).We analyzed 311 OSCC patients with Ns: 77 (24.76%) with and 234 (75.24%) without ENE. Lymph node (LN) >3 cm was the only significant factor associated with ENE (odds ratio 17.21, p < 0.001). The 5-year, disease-free survival of N1/N2A and N3B patients was 60.5% and 49.4%, respectively (p = 0.04), and the 5-year overall survival was 63.1% and 33.6%, respectively (p = 0.0001). Four fifths of Ns patients with LN >3 cm were upgraded to N3B category as ENE+. Postoperative radiotherapy (PORT) could provide significant benefit in regional control for Ns patients with (p = 0.03) and without (p = 0.0004) other adverse features. After multivariant Cox analysis, ENE+ was a modest and significant risk factor for disease-free (p = 0.08) and overall survival (p = 0.001). By contrast, the LN>3cm and N2A category were not significant risk factors for disease-free and overall survival.For OSCC patients with Ns, the survival outcome between N3B category and N1/N2A category was significantly different. After ENE+ upgrades (>80%), there were fewer N2A patients, and these patients became more comparable to N1 patients. PORT could significantly improve regional control for Ns patients.© 2023. Society of Surgical Oncology.